Differentiation of low and high grade renal cell carcinoma on routine MRI with an externally validated automatic machine learning algorithm.

Journal: Scientific reports
Published Date:

Abstract

Pre-treatment determination of renal cell carcinoma aggressiveness may help guide clinical decision-making. We aimed to differentiate low-grade (Fuhrman I-II) from high-grade (Fuhrman III-IV) renal cell carcinoma using radiomics features extracted from routine MRI. 482 pathologically confirmed renal cell carcinoma lesions from 2008 to 2019 in a multicenter cohort were retrospectively identified. 439 lesions with information on Fuhrman grade from 4 institutions were divided into training and test sets with an 8:2 split for model development and internal validation. Another 43 lesions from a separate institution were set aside for independent external validation. The performance of TPOT (Tree-Based Pipeline Optimization Tool), an automatic machine learning pipeline optimizer, was compared to hand-optimized machine learning pipeline. The best-performing hand-optimized pipeline was a Bayesian classifier with Fischer Score feature selection, achieving an external validation ROC AUC of 0.59 (95% CI 0.49-0.68), accuracy of 0.77 (95% CI 0.68-0.84), sensitivity of 0.38 (95% CI 0.29-0.48), and specificity of 0.86 (95% CI 0.78-0.92). The best-performing TPOT pipeline achieved an external validation ROC AUC of 0.60 (95% CI 0.50-0.69), accuracy of 0.81 (95% CI 0.72-0.88), sensitivity of 0.12 (95% CI 0.14-0.30), and specificity of 0.97 (95% CI 0.87-0.97). Automated machine learning pipelines can perform equivalent to or better than hand-optimized pipeline on an external validation test non-invasively predicting Fuhrman grade of renal cell carcinoma using conventional MRI.

Authors

  • Subhanik Purkayastha
    Department of Diagnostic Imaging, Warren Alpert Medical School of Brown University, Providence, Rhode Island.
  • Yijun Zhao
    Department of Computer Science, Tufts University, Medford, Massachusetts, United States of America.
  • Jing Wu
    School of Pharmaceutical Science, Jiangnan University, Wuxi, 214122, Jiangsu, China.
  • Rong Hu
    College of Chemistry and Chemical Engineering, Yunnan Normal University , Yunnan, Kunming, 650092, People's Republic of China.
  • Aidan McGirr
    Department of Radiology, Mayo Clinic, Phoenix, AZ, USA.
  • Sukhdeep Singh
    Department of Radiology, Mayo Clinic, Phoenix, AZ, USA.
  • Ken Chang
    Athinoula A. Martinos Center for Biomedical Imaging, Department of Radiology, Massachusetts General Hospital, Boston, Massachusetts.
  • Raymond Y Huang
    Department of Radiology, Brigham and Women's Hospital, Boston, Massachusetts. kalpathy@nmr.mgh.harvard.edu yangli762@gmail.com ryhuang@partners.org.
  • Paul J Zhang
    Department of Pathology and Laboratory Medicine, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania.
  • Alvin Silva
    Department of Radiology, Mayo Clinic, Phoenix, AZ, USA.
  • Michael C Soulen
    Department of Radiology, Division of Interventional Radiology, Perelman School of Medicine of the University of Pennsylvania, Philadelphia, Pennsylvania.
  • S William Stavropoulos
    Department of Radiology, Division of Interventional Radiology, Perelman School of Medicine of the University of Pennsylvania, Philadelphia, Pennsylvania. S.Stavropoulos@uphs.upenn.edu Harrison_Bai@Brown.edu zishuzhang@csu.edu.cn.
  • Zishu Zhang
    Department of Radiology, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China. S.Stavropoulos@uphs.upenn.edu Harrison_Bai@Brown.edu zishuzhang@csu.edu.cn.
  • Harrison X Bai
    Department of Radiology, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania.